Hepatic hepcidin protects against polymicrobial sepsis in mice by regulating host iron status

Anesthesiology

Volumn 122, Issue 2, 2015, Pages 374-386

  Zeng, Congli ^a   Chen, Qixing ^a   Zhang, Kai ^a   Chen, Qinghua ^a   Song, Shengwen ^a   Fang, Xiangming ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPCIDIN; IRON; SHORT HAIRPIN RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; CELL LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE SILENCING; INFLAMMATION; IRON BLOOD LEVEL; IRON CHELATION; IRON METABOLISM; IRON RESTRICTION; LIVER DISEASE; MACROPHAGE; MALE; METABOLIC REGULATION; MORTALITY; MOUSE; NONHUMAN; ORGAN INJURY; OXIDATIVE STRESS; PATHOGENESIS; POLYMICROBIAL SEPSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEPSIS; SPLEEN MACROPHAGE; SURVIVAL RATE; ANIMAL; BACTERIAL COUNT; BAGG ALBINO MOUSE; BLOOD; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; LIVER FUNCTION TEST; METABOLISM; MICROBIOLOGY; NUTRITIONAL STATUS; PHAGOCYTOSIS; PHYSIOLOGY; SPLEEN;

ANIMALS; COLONY COUNT, MICROBIAL; HEPCIDINS; IRON; LIVER FUNCTION TESTS; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NADPH OXIDASE; NUTRITIONAL STATUS; PHAGOCYTOSIS; SEPSIS; SPLEEN;

EID: 84922069986     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000000466     Document Type: Article

References (65)

1. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-50
2. Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005; 365:63-78
3. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-54
4. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D; Sepsis Occurrence in Acutely Ill Patients Investigators: Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006; 34:344-53
5. Cheng B, Xie G, Yao S, Wu X, Guo Q, Gu M, Fang Q, Xu Q, Wang D, Jin Y, Yuan S, Wang J, Du Z, Sun Y, Fang X: Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 2007; 35:2538-46
6. Leentjens J, Kox M, van der Hoeven JG, Netea MG, Pickkers P: Immunotherapy for the adjunctive treatment of sepsis: From immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med 2013; 187:1287-93
7. Rittirsch D, Flierl MA, Ward PA: Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8:776-87
8. Dhainaut JF, Marin N, Mignon A, Vinsonneau C: Hepatic response to sepsis: Interaction between coagulation and inflammatory processes. Crit Care Med 2001; 29(7 suppl):S42-7
9. Lescot T, Karvellas C, Beaussier M, Magder S: Acquired liver injury in the intensive care unit. Anesthesi ology 2012; 117:898-904
10. Marshall JC: New translational research provides insights into liver dysfunction in sepsis. PLoS Med 2012; 9:e1001341
11. Bauer M, Press AT, Trauner M: The liver in sepsis: Patterns of response and injury. Curr Opin Crit Care 2013; 19:123-7
12. Vandevyver S, Dejager L, Vandenbroucke RE, Libert C: An acute phase protein ready to go therapeutic for sepsis. EMBO Mol Med 2014; 6:2-3
13. Ganz T: Hepcidin and iron regulation, 10 years later. Blood 2011; 117:4425-33
14. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101:2461-3
15. Drakesmith H, Prentice AM: Hepcidin and the iron-infection axis. Science 2012; 338:768-72
16. Muckenthaler MU: Fine tuning of hepcidin expression by positive and negative regulators. Cell Metab 2008; 8:1-3
17. Ganz T, Nemeth E: Hepcidin and disorders of iron metabolism. Annu Rev Med 2011; 62:347-60
18. Lasocki S, Longrois D, Montravers P, Beaumont C: Hepcidin and anemia of the critically ill patient. Anesthesi ology 2011; 114:688-94
19. Hentze MW, Muckenthaler MU, Galy B, Camaschella C: Two to tango: Regulation of mammalian iron metabolism. Cell 2010; 142:24-38
20. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S: Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A 2002; 99:4596-601
21. Lesbordes-Brion JC, Viatte L, Bennoun M, Lou DQ, Ramey G, Houbron C, Hamard G, Kahn A, Vaulont S: Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood 2006; 108:1402-5
22. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, Subramaniam VN, Powell LW, Anderson GJ, Ramm GA: Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003; 361:669-73
23. O riga R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E: Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica 2007; 92:583-8
24. Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, Muirhead K, Rao N, Roy CN, Andrews NC, Nemeth E, Follenzi A, An X, Mohandas N, Ginzburg Y, Rachmilewitz EA, Giardina PJ, Grady RW, Rivella S: Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J Clin Invest 2010; 120:4466-77
25. Huang YH, Yang YL, Tiao MM, Kuo HC, Huang LT, Chuang JH: Hepcidin protects against lipopolysaccharide-induced liver injury in a mouse model of obstructive jaundice. Peptides 2012; 35:212-7
26. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D: Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005; 106:1864-6
27. van Eijk LT, Kroot JJ, Tromp M, van der Hoeven JG, Swinkels DW, Pickkers P: Inflammation-induced hepcidin-25 is associated with the development of anemia in septic patients: An observational study. Crit Care 2011; 15:R9
28. Lou DQ, Nicolas G, Lesbordes JC, Viatte L, Grimber G, Szajnert MF, Kahn A, Vaulont S: Functional differences between hepcidin 1 and 2 in transgenic mice. Blood 2004; 103:2816-21
29. Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, Winters A, Juan T, Li H, Begley CG, Molineux G: Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010; 115:3616-24
30. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, Lieberman J: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-51
31. Chen Q, Zhang K, Jin Y, Zhu T, Cheng B, Shu Q, Fang X: Triggering receptor expressed on myeloid cells-2 protects against polymicrobial sepsis by enhancing bacterial clearance. Am J Respir Crit Care Med 2013; 188:201-12
32. D'Alessio FR, Tsushima K, Aggarwal NR, West EE, Willett MH, Britos MF, Pipeling MR, Brower RG, Tuder RM, McDyer JF, King LS: CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Clin Invest 2009; 119:2898-913
33. Hofer H, Osterreicher C, Jessner W, Penz M, Steindl-Munda P, Wrba F, Ferenci P: Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 2004; 40:1018-22
34. Zhang AS, Gao J, Koeberl DD, Enns CA: The role of hepatocyte hemojuvelin in the regulation of bone morphogenic protein-6 and hepcidin expression in vivo. J Biol Chem 2010; 285:16416-23
35. Callera GE, Tostes RC, Yogi A, Montezano AC, Touyz RM: Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms. Clin Sci (Lond) 2006; 110:243-53
36. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, Schiffrin EL: Expression of a functionally active gp91phoxcontaining neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: Regulation by angiotensin II. Circ Res 2002; 90:1205-13
37. Hart L, Rauch A, Carr AM, Vermeesch JR, O'Driscoll M: LETM1 haploinsufficiency causes mitochondrial defects in cells from humans with Wolf-Hirschhorn syndrome: Implications for dissecting the underlying pathomechanisms in this condition. Dis Model Mech 2014; 7:535-45
38. Pietrangelo A: Hepcidin in human iron disorders: Therapeutic implications. J Hepatol 2011; 54:173-81
39. Ganz T: Iron in innate immunity: Starve the invaders. Curr Opin Immunol 2009; 21:63-7
40. Kuo KL, Hung SC, Wei YH, Tarng DC: Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 2008; 19:1817-26
41. Fibach E, Rachmilewitz EA: The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia. Ann N Y Acad Sci 2010; 1202:10-6
42. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K: LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480:147-50
43. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU: STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007; 109:353-8
44. Peyssonnaux C, Zinkernagel AS, Datta V, Lauth X, Johnson RS, Nizet V: TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 2006; 107:3727-32
45. Wu S, Zhang K, Lv C, Wang H, Cheng B, Jin Y, Chen Q, Lian Q, Fang X: Nuclear factor-κB mediated lipopolysaccharideinduced mRNA expression of hepcidin in human peripheral blood leukocytes. Innate Immun 2012; 18:318-24
46. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S: Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001; 98:8780-5
47. Polati R, Castagna A, Bossi AM, Alberio T, De Domenico I, Kaplan J, Timperio AM, Zolla L, Gevi F, D'Alessandro A, Brunch R, Olivieri O, Girelli D: Murine macrophages response to iron. J Proteomics 2012; 76 Spec No.:10-27
48. O lakanmi O, Schlesinger LS, Britigan BE: Hereditary hemochromatosis results in decreased iron acquisition and growth by Mycobacterium tuberculosis within human macrophages. J Leukoc Biol 2007; 81:195-204
49. Nairz M, Theurl I, Schroll A, Theurl M, Fritsche G, Lindner E, Seifert M, Crouch ML, Hantke K, Akira S, Fang FC, Weiss G: Absence of functional Hfe protects mice from invasive Salmonella enterica serovar Typhimurium infection via induction of lipocalin-2. Blood 2009; 114:3642-51
50. Pagani A, Nai A, Corna G, Bosurgi L, Rovere-Querini P, Camaschella C, Silvestri L: Low hepcidin accounts for the proinflammatory status associated with iron deficiency. Blood 2011; 118:736-46
51. Wang L, Harrington L, Trebicka E, Shi HN, Kagan JC, Hong CC, Lin HY, Babitt JL, Cherayil BJ: Selective modulation of TLR4-activated inflammatory responses by altered iron homeostasis in mice. J Clin Invest 2009; 119:3322-8
52. Wang L, Johnson EE, Shi HN, Walker WA, Wessling-Resnick M, Cherayil BJ: Attenuated inflammatory responses in hemochromatosis reveal a role for iron in the regulation of macrophage cytokine translation. J Immunol 2008; 181: 2723-31
53. Yu C, York B, Wang S, Feng Q, Xu J, O'Malley BW: An essential function of the SRC-3 coactivator in suppression of cytokine mRNA translation and inflammatory response. Mol Cell 2007; 25:765-78
54. Anderson P: Post-transcriptional control of cytokine production. Nat Immunol 2008; 9:353-9
55. Canabal JM, Kramer DJ: Management of sepsis in patients with liver failure. Curr Opin Crit Care 2008; 14:189-97
56. Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F: The systemic inflammatory response syndrome in cirrhotic patients: Relationship with their in-hospital outcome. J Hepatol 2009; 51:475-82
57. Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, Rodés J: Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35:140-8
58. Foreman MG, Mannino DM, Moss M: Cirrhosis as a risk factor for sepsis and death: Analysis of the National Hospital Discharge Survey. Chest 2003; 124:1016-20
59. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R: Severe sepsis in cirrhosis. Hepatology 2009; 50:2022-33
60. Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, Patch D, Soriano G, Hoefs J, Navasa M; International Ascites Club: Sepsis in cirrhosis: Report on the 7th meeting of the International Ascites Club. Gut 2005; 54:718-25
61. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA: Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008; 48:1420-9
62. Bergmann OM, Mathahs MM, Broadhurst KA, Weydert JA, Wilkinson N, Howe JR, Han O, Schmidt WN, Brown KE: Altered expression of iron regulatory genes in cirrhotic human livers: Clues to the cause of hemosiderosis? Lab Invest 2008; 88:1349-57
63. Harrison-Findik DD, Klein E, Crist C, Evans J, Timchenko N, Gollan J: Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology 2007; 46:1979-85
64. Kijima H, Sawada T, Tomosugi N, Kubota K: Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer 2008; 8:167
65. Huang YH, Chuang JH, Yang YL, Huang CC, Wu CL, Chen CL: Cholestasis downregulate hepcidin expression through inhibiting IL-6-induced phosphorylation of signal transducer and activator of transcription 3 signaling. Lab Invest 2009; 89:1128-39